Neurim’s patent for mini melatonin put to sleep
Intellectual Property 2022-12-05 10:50 pm By Sam Matthews | Melbourne
Please login to bookmark Close

Israeli drug company Neurim Pharmaceuticals has lost a bid to patent a mini version of its melatonin tablet Circadin for children, after a successful challenge by Australian drug maker Generic Partners.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au